Robin Foà

Robin Foà

UNVERIFIED PROFILE

Are you Robin Foà?   Register this Author

Register author
Robin Foà

Robin Foà

Publications by authors named "Robin Foà"

Are you Robin Foà?   Register this Author

100Publications

1905Reads

22Profile Views

Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: a single-center experience.

Blood Coagul Fibrinolysis 2019 Sep;30(6):304-307

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000835DOI Listing
September 2019

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Ann Hematol 2019 Aug 11;98(8):1891-1904. Epub 2019 May 11.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03706-xDOI Listing
August 2019

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Ann Hematol 2019 Aug 5;98(8):1919-1925. Epub 2019 Jun 5.

Hematology, Department of Precision and Translational Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03724-9DOI Listing
August 2019

Direct Oral Anticoagulants in Patients Affected by Major Congenital Thrombophilia.

Mediterr J Hematol Infect Dis 2019 1;11(1):e2019044. Epub 2019 Jul 1.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2019.044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613626PMC
July 2019

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Hematol Oncol 2019 Jul 19. Epub 2019 Jul 19.

Hematology, Department of Translational and Precision Medicine, University 'Sapienza' and Policlinico Umberto 1, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2650DOI Listing
July 2019

Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.

Acta Haematol 2019 21;142(3):185-186. Epub 2019 May 21.

Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497137DOI Listing
May 2019

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Ther Adv Hematol 2019 1;10:2040620719826444. Epub 2019 Mar 1.

Haematology, Department of Cellular Biotechnologies and Haematology, Azienda Ospedaliera, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719826444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399752PMC
March 2019

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Mediterr J Hematol Infect Dis 2019 1;11(1):e2019024. Epub 2019 Mar 1.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2019.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402553PMC
March 2019

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Br J Haematol 2019 Feb 18;184(3):392-396. Epub 2018 Oct 18.

Department of Cellular Biotechnologies and Haematology, "Sapienza" University, Rome, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15613
Publisher Site
http://dx.doi.org/10.1111/bjh.15613DOI Listing
February 2019

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2019 Feb 7;12(2):81-87. Epub 2019 Jan 7.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
February 2019

Another step forward in the 20-year history of mutations in chronic lymphocytic leukemia.

Haematologica 2019 Feb;104(2):219-221

Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.207399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355490PMC
February 2019

BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?

Cancer 2019 Jan 18;125(2):194-204. Epub 2018 Dec 18.

Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31848DOI Listing
January 2019

Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia.

Eur J Intern Med 2018 12;58:22-27

Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2018.05.028DOI Listing
December 2018

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Ann Hematol 2018 Oct 27;97(10):1803-1808. Epub 2018 May 27.

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3375-9DOI Listing
October 2018

Current and future therapeutic approaches for the treatment of follicular lymphoma.

Expert Rev Anticancer Ther 2018 09 16;18(9):931-941. Epub 2018 Jul 16.

a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1493926DOI Listing
September 2018

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Br J Haematol 2018 08 5;182(3):427-429. Epub 2017 Jul 5.

Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14783DOI Listing
August 2018

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Expert Rev Hematol 2018 08 18;11(8):601-611. Epub 2018 Jul 18.

a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University and Policlinico Umberto 1 , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1495557DOI Listing
August 2018

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2018 04 17;181(2):275-278. Epub 2017 Feb 17.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14560DOI Listing
April 2018

Gene mutations in lenalidomide-treated CLL.

Blood 2018 04;131(16):1769-1771

Sapienza University of Rome.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-02-830406DOI Listing
April 2018

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

Curr Oncol Rep 2018 03 6;20(3):23. Epub 2018 Mar 6.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0669-yDOI Listing
March 2018

Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.

Lancet Oncol 2018 01 12;19(1):7-8. Epub 2017 Dec 12.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30910-5DOI Listing
January 2018

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

Am J Hematol 2017 Dec 19;92(12):E661-E664. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24913
Publisher Site
http://dx.doi.org/10.1002/ajh.24913DOI Listing
December 2017

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Am J Hematol 2017 12 19;92(12):E668-E670. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24916DOI Listing
December 2017

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Cancer Immunol Immunother 2017 Nov 18;66(11):1473-1484. Epub 2017 Jul 18.

TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Medicinaregatan 1F, Box 425, 413 90, Gothenburg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2040-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645432PMC
November 2017

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Haematol 2017 Nov 25;4(11):e534-e543. Epub 2017 Sep 25.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(17)30168-0DOI Listing
November 2017

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?

Expert Rev Hematol 2017 09 25;10(9):761-774. Epub 2017 Jul 25.

a Department of Cellular Biotechnologies and Hematology , Sapienza University of Rome , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1356714DOI Listing
September 2017

Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.

Br J Haematol 2017 05 17;177(4):588-596. Epub 2017 Apr 17.

Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto I, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14616DOI Listing
May 2017

Diffuse large B-cell lymphoma genotyping on the liquid biopsy.

Blood 2017 04 17;129(14):1947-1957. Epub 2017 Jan 17.

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-05-719641DOI Listing
April 2017

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

N Engl J Med 2017 03;376(9):836-847

From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (H.K.); City of Hope National Medical Center, Duarte (A.S.), and Amgen, Thousand Oaks (A.F., D.N., Z.Z.) - both in California; Goethe University, University Hospital, Department of Medicine II, Frankfurt am Main (N.G.), Medical Department II (H.-A.H., M.B.) and Hematopathology Section and Lymph Node Registry (W.K.), University Hospital Schleswig Holstein, Campus Kiel, Kiel, and Medizinische Klinik und Poliklinik II, Universitätsklinikums Würzburg, Würzburg (M.S.T.) - all in Germany; Royal Free Hospital and University College London Cancer Institute, London (A.K.F.); Princess Margaret Cancer Centre, Toronto (A.C.S.), and Centre Intégré Universitaire de Santé et de Services Sociaux de l'est de l'île de Montréal, Hôpital Maisonneuve-Rosemont, Montreal (J.B.) - all in Canada; ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barcelona (J.-M.R.), the Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid (M.A.S.) - all in Spain; Alfred Hospital and Monash University, Melbourne, VIC, Australia (A.W.); Institut Universitaire d'Hématologie, Hôpital Saint-Louis (Assistance Publique - Hôpitaux de Paris), Paris (H.D.), and Centre Hospitalier Lyon Sud, Pierre-Benite (X.T.) - both in France; Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Azienda Ospedaliera Policlinico Umberto I, Università Sapienza di Roma, Rome (R.F.), Azienda Unità Locale Socio Sanitaria 12 Veneziana Ospedale Dell Angelo, Venice (R.B.), and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Università Statale di Milano, Milan (A.R.) - all in Italy; Ankara Universitesi, Tip Fakültesi, Cebeci Arastirma ve Uygulama Hastanesi, Ankara (Ö.A.), and Dokuz Eylül Üniversitesi Tıp Fakültesi, İzmir (F.D.) - both in Turkey; Instytut Hematologii i Transfuzjologii and Centrum Medyczne Kształcenia Podyplomowego, Warsaw, Poland (E.L.-M.); University of Washington Medical Center, Seattle (B.L.W.); and Amgen, Washington, DC (C.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881572PMC
March 2017